Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID IM027-1015  |   NCT06025578

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Summary

  • Phase 3
  • Male and Female Gender icon
  • 21+
    Age Range
  • 261
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Diagnosis of interstitial lung disease (ILD) with features consistent with progressive ILD within 24 months prior to screening, and ≥ 10% extent of fibrosis on screening high-resolution computed tomography (HRCT).
    1. If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening.
      1. If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening.
        1. Mycophenolate mofetil (MMF), mycophenolic acid (MA), azathioprine (AZA), and Tacrolimus are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on MMF, MA, AZA, or tacrolimus, participants must not have taken these medications within 28 days prior to screening.
          1. Traditional disease-modifying antirheumatic drug (DMARDs) (eg. Methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on traditional DMARD, participants must not have taken these medications within 28 days prior to screening.
            1. Biologic DMARDs (eg. TNF blockers and IL-1 inhibitors) and Janus kinase inhibitors (JAK inhibitors eg. tofacitinib, upadacitinib) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on Biologic DMARD or JAK inhibitor, participants must not have taken these medications within 28 days prior to screening.
              1. Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test.
                1. Men who are sexually active with women of childbearing potential agree to use male barrier contraception.

                  Exclusion Criteria

                  Exclusion Criteria Icon
                  • Idiopathic pulmonary fibrosis with usual interstitial pneumonia (UIP) verification at screening.
                    1. History of stroke or transient ischemic attack within 3 months prior to screening.
                      1. Participants who exhibit symptoms of heart failure at rest.
                        1. Participants who have a current malignancy or a previous malignancy in the past 5 years prior to screening, except for those who have a documented history of cured nonmetastatic squamous cell skin carcinoma, basal cell skin carcinoma, or cervical carcinoma in situ.
                          1. Use of systemic corticosteroids equivalent to prednisone > 15 mg/day is not allowed within 4 weeks prior to screening and during the study.
                            Additional Information *
                            • Other protocol-defined Inclusion/Exclusion criteria apply.

                              Treatment Options

                              Study Arms

                              ASSIGNED INTERVENTION

                              Study Arms

                              Experimental: BMS-986278 Dose 1

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986278

                              Study Arms

                              Experimental: BMS-986278 Dose 2

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986278

                              Study Arms

                              Placebo Comparator: BMS-986278 Placebo

                              ASSIGNED INTERVENTION
                              • Drug: BMS-986278 Placebo
                              Take the first step to see if you Match to a Clinical Trial – Check if you qualify
                              Check if you qualify
                              Answer some questions about Your health to see if you may match to this trial
                              Match to a Trial
                              If you are a match, click on the study to see the list of study site locations
                              Select a Study Site Location
                              Select a study site location that is convenient for you
                              Register
                              Provide your contact details for the study site to connect with you.

                              Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you